KOSDAQIT & Software032850

BITComputer

₩3,795▼ 0.91%2026-11-18 close
Market Cap
₩63.1B
Turnover
₩46,368,390
Volume
10K
Shares out.
16.6M
PER
7.0×
PBR
0.8×
EPS
₩551
Dividend Yield
1.72%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩66 per share · Prices as of the 2026-11-18 close

01

Report overview

Operating profit up three straight quarters; durability of recovery is the test

BITComputer's operating profit has risen for three consecutive quarters since the first quarter of 2026, but full-year 2025 operating profit fell from the prior year, so whether the recovery lasts is a question for the next annual report.

  1. 1

    Operating profit in Q3 2026 was KRW 2.42 billion, up 33.1% from the prior quarter and 64.7% from a year earlier, while revenue rose 15.3% year on year.

  2. 2

    Full-year 2025 operating profit was KRW 5.86 billion, down 12.1% from the prior year, and the 16.3% operating margin was the lowest of 2022 to 2025.

  3. 3

    At the end of 2025, total liabilities were KRW 8.95 billion against total equity of KRW 73.8 billion, and the debt-to-equity ratio of 12.1% was the lowest of the four years.

  4. 4

    Share buyback decisions were disclosed five times in 2026, in January, May, June, July and September, and the September 17 decision runs until December 8, 2026.

  5. 5

    The medical information systems segment accounted for 78.7% of revenue in the first nine months of 2023, making it the core of the business and the main driver of earnings swings.

02

Business structure

BITComputer is a medical information company founded in 1983 and listed on KOSDAQ in 1997, and it holds three unlisted subsidiaries. It develops and supplies medical information systems that integrate EMR, OCS and HIS, and its company profile describes it as holding the top market share in this field.

The business is divided into medical information systems and digital healthcare. A securities research report from January 2024 put the medical information systems share at 78.7% of revenue in the first nine months of 2023.

By domestic and export mix in the 2023 full year, medical information systems were 92.57% domestic, while digital healthcare was 62.53% domestic and 37.47% exported.

Its main products are bitnixHIS for mid-to-large hospitals and the cloud-based EMR Clemer for small and mid-sized clinics, and the company's earnings commentary cited expansion of these two lines as a driver of revenue growth.

The digital healthcare unit includes the telemedicine platform Barodoctor, launched in September 2023. Its main customers are hospitals and clinics, and an April 2021 securities technical analysis report put domestic revenue at 96.3%.

The company is pursuing data-driven services and leadership in AI analytics platforms by adding cloud EMR and AI voice charting features. Several vendors supply cloud-based clinic EMR software, so competition over features and hospital wins continues.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩8.5B₩1.5B17.4%
2025Q4₩10.7B₩1.4B12.7%
2026Q1₩9.6B₩1.8B18.4%
2026Q2₩9.8B₩1.8B18.6%
2026Q3₩9.7B₩2.4B24.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩35.1B₩6.1B₩4.9B17.5%7.8%17.7%
2023₩33.5B₩6.2B₩5.5B18.6%8.4%21.0%
2024₩37.1B₩6.7B₩7.8B18.0%11.0%13.1%
2025₩36B₩5.9B₩7.4B16.3%10.0%12.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

On the basis of the filed results, annual revenue was KRW 35.1 billion in 2022, KRW 33.5 billion in 2023, KRW 37.1 billion in 2024 and KRW 36 billion in 2025. Revenue fell 4.8% in 2023 and then rose 10.8% in 2024, making 2024 the largest year of 2022 to 2025, before slipping 2.9% in 2025.

Operating profit went from KRW 6.15 billion in 2022 to KRW 6.22 billion in 2023 (up 1.2%) and KRW 6.67 billion in 2024 (up 7.2%), then fell to KRW 5.86 billion in 2025 (down 12.1%), the smallest year of the period.

The operating margin moved from 17.5% in 2022 to 18.6% in 2023 and 18.0% in 2024, then fell to 16.3% in 2025. In 2025 operating profit fell faster than revenue, so the margin was squeezed.

Net profit attributable to controlling shareholders rose from KRW 4.87 billion in 2022 to KRW 7.76 billion in 2024 (up 40.1% in 2024 from the prior year) and then fell to KRW 7.37 billion in 2025 (down 5.0%).

Net profit including non-controlling interests, which is a different figure, was KRW 7.33 billion in 2025, below KRW 7.47 billion in 2024. Operating cash flow ranged from KRW 6.17 billion in 2022 to KRW 7.89 billion in 2023, KRW 5.2 billion in 2024 and KRW 7.05 billion in 2025.

In the quarters, revenue of KRW 8.45 billion and operating profit of KRW 1.47 billion in Q3 2025 were followed by revenue of KRW 10.7 billion in Q4 2025, up 26.8% from the prior quarter, while operating profit slipped to KRW 1.36 billion, down 7.7%.

Revenue then fell 10.3% to KRW 9.61 billion in Q1 2026, while operating profit rose 30.6% to KRW 1.77 billion. Operating profit reached KRW 1.82 billion in Q2 2026 and KRW 2.42 billion in Q3 2026.

Net profit attributable to controlling shareholders was KRW 2.16 billion in Q3 2026, and the KRW 2.37 billion in Q2 2026 was the highest of the last five quarters. The four quarters from Q4 2025 to Q3 2026 total KRW 8.24 billion in net profit attributable to controlling shareholders. The reason for the Q4 2025 operating profit decline is a cost-line question to check in the annual report.

05

Industry analysis

Core demand in the domestic medical information market comes from hospital electronic medical records and clinical and prescription systems, and BITComputer's company profile says it holds the top market share in this field.

The shift of hospital IT to the cloud is cited as a driver of revenue growth from Clemer, its cloud EMR aimed at small and mid-sized clinics.

The passage of a medical law amendment on telemedicine established the legal basis for remote care platforms, which is a favorable policy backdrop for the digital healthcare unit.

Demand for cloud EMR and AI-based diagnosis and prediction is also raising the value of medical information systems, according to the same source. On the other side, several vendors supply similar cloud-based clinic EMR products, so price and feature competition persists.

The company responds by offering separate product lines for different hospital sizes. Domestic sales made up 92.57% of medical information systems in the 2023 full year, so the business depends heavily on hospital IT spending in Korea. The sector therefore moves with hospitals' IT budgets and with changes in telemedicine rules.

06

Outlook

The company's stated direction is to build leadership in data-driven services and AI analytics platforms on cloud EMR and AI voice charting features. Operating profit has risen for three consecutive quarters through Q3 2026, and the KRW 2.42 billion in Q3 2026 is the highest in the filed quarterly results.

However, Q3 2026 revenue of KRW 9.74 billion was below the KRW 10.7 billion of Q4 2025, so it is not yet confirmed whether revenue and profit are recovering at the same pace.

Share buyback decisions have been made several times since January 2026, and the September 17, 2026 board decision covers 260,000 shares for about KRW 1.0 billion, to be bought on the open market from September 18 to December 8, 2026.

The company stated the purpose is price stabilization and shareholder value enhancement. As of a June 12, 2026 filing, Chairman and CEO Jo Hyun-jung's stake rose to 24.93%, and as of a July 13, 2026 filing, unregistered director Jo Jae-seok held a 1.40% stake.

Treasury shares held total 2,470,238 shares according to the disclosure, and their significance depends on future cancellation or disposal decisions. The 2026 annual report, the next periodic filing, will confirm the Q4 2026 results and the full-year operating margin.

07

Valuation

PER
7.0×
PBR
0.8×
ROE
11.3%
EPS
₩551
BPS
₩4,921
Dividend per share
₩66

Share price levels are best compared against the company's own past valuation and its multiple of book value. A January 2024 securities research report put the 2024 forward PER at 17.1 times, and the current multiple is low relative to that reference.

The price-to-book ratio is below 1 times, which means the shares trade at a price below net asset value. The dividend yield was above the average of the KOSDAQ IT services sector in the 2023 full-year comparison, and changes in dividend levels since then should be checked against new filings.

Based on the KRW 8.24 billion of net profit attributable to controlling shareholders over the last four quarters, the company is small, so its multiples can move sharply with quarterly earnings. Profit fell in 2025 and then recovered in 2026, which has lowered the earnings-based multiple compared with earlier levels.

Repeated share buybacks are a disclosed fact tied to price stabilization, with each program at roughly KRW 1.0 billion. This section covers factual comparisons of valuation levels and does not contain a view on the direction of the share price.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Operating profit recovery

Operating profit rose to KRW 1.77 billion in Q1 2026, KRW 1.82 billion in Q2 and KRW 2.42 billion in Q3, three consecutive quarterly gains. Q3 2026 operating profit grew 64.7% year on year, well ahead of 15.3% revenue growth. If this continues, it could offset the full-year 2025 decline, which is the core of the bullish case.

Cloud EMR and policy backdrop

The company is adding cloud EMR and AI voice charting features, and its earnings commentary cited Clemer's contribution for small and mid-sized clinics. The passage of a telemedicine amendment established a legal basis for remote care platforms. Both factors are structural drivers that could expand demand for medical information systems.

Balance sheet and shareholder return disclosures

At the end of 2025 the debt-to-equity ratio was 12.1%, with total equity of KRW 73.8 billion and total liabilities of KRW 8.95 billion. Share buyback decisions were disclosed five times in 2026, and the latest program runs until December 8, 2026. The repeated return of capital on a light debt base is the bullish side of the balance sheet.

09

Bear factors

2025 profit decline and margin pressure

Operating profit fell 12.1% to KRW 5.86 billion in 2025, and the 16.3% margin was the lowest of 2022 to 2025. Q4 2025 revenue rose to KRW 10.7 billion while operating profit slipped to KRW 1.36 billion. The period in which higher revenue did not translate into profit is the bearish point.

Flat revenue base

Annual revenue moved between KRW 33.5 billion and KRW 37.1 billion over 2022 to 2025, and fell 2.9% in 2025. Quarterly revenue of KRW 9.61 billion in Q1 2026, KRW 9.79 billion in Q2 and KRW 9.74 billion in Q3 has moved sideways without a large step up. Limited top-line growth is the main bearish concern.

Ownership structure and free float

Chairman and CEO Jo Hyun-jung held 24.93% as of a June 12, 2026 filing. The free-float ratio was reported at 57.74%. High insider and treasury holdings can limit trading liquidity, which is the bearish side of the share structure.

10

Risk factors

Policy and regulatory risk

Demand for digital healthcare and telemedicine depends on medical laws and how they are implemented. Even after the amendment passed, the scope of the business can differ depending on detailed enforcement rules. Regulatory change is a variable the company cannot control directly.

Earnings volatility

Quarterly operating profit ranged from KRW 1.36 billion in Q4 2025 to KRW 2.42 billion in Q3 2026, a wide swing for a company of this size. A single change in hospital orders or costs can move quarterly profit noticeably. The cost driver behind the Q4 2025 decline still needs to be confirmed.

Governance and supply-demand risk

Buyback decisions have been repeated in 2026, and treasury shares held total 2,470,238 shares per the disclosure. Future buybacks, cancellations or disposals could affect the outstanding share count and trading supply. With a high controlling-shareholder stake, changes in share supply can have a large effect on the share price.

11

What to watch next

  1. December 8, 2026

    The expiry of the treasury share purchase period set by the September 17, 2026 board decision, covering up to 263,000 shares for about KRW 1.0 billion. The actual number of shares and amount acquired, and completion as reported in the results filing, should be checked.

  2. Late March 2027

    The filing deadline for the 2026 annual report, when Q4 2026 results and the full-year operating margin are first confirmed. The cost cause behind the Q4 2025 operating profit decline and the annual revenue structure should also be checked in this report.

  3. May 15, 2027

    The filing deadline for the Q1 2027 quarterly report. It will show whether revenue recovers from the Q4 2026 level and whether the operating margin holds near the Q3 2026 level.

12

Overall view

BITComputer's operating profit has risen for three consecutive quarters in 2026 after the decline in 2025, showing a recovery trend. Q3 2026 operating profit of KRW 2.42 billion was up 64.7% from a year earlier.

However, full-year 2025 operating profit fell 12.1% to KRW 5.86 billion, and the 16.3% margin was the lowest of 2022 to 2025. Revenue has moved between KRW 33.5 billion and KRW 37.1 billion over 2022 to 2025, and top-line growth has not been pronounced.

On the balance sheet, a 12.1% debt-to-equity ratio and KRW 73.8 billion in total equity at the end of 2025 indicate a light debt burden. Buyback decisions have been disclosed repeatedly in 2026, and the current program runs until December 8, 2026.

On the other side, the high controlling-shareholder stake and low free float constrain the trading structure. The next checkpoint is the Q4 2026 results and full-year operating margin in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. comp.wisereport.co.kr
  4. comp.fnguide.com
  5. thevc.kr
  6. ssl.pstatic.net
  7. ssl.pstatic.net
  8. investing.com
  9. comp.fnguide.com
  10. datatooza.com
  11. digitaltoday.co.kr
  12. digitaltoday.co.kr
  13. datatooza.com
  14. digitaltoday.co.kr
  15. digitaltoday.co.kr
  16. news.nate.com
  17. digitaltoday.co.kr
  18. m.news.nate.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis